Samsung Biologics’ announcement to split into a contract drug manufacturer and a holding company has caused fluctuations in C&T shares. This move signals a significant restructuring within South Korea’s largest conglomerate. The plan aims to streamline operations by separating the manufacturing arm from the oversight and management functions, potentially enhancing overall efficiency and focus in […]